Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy.

Kyriakides M, Rama N, Sidhu J, Gabra H, Keun HC, El-Bahrawy M.

Oncotarget. 2016 Feb 9;7(6):7216-26. doi: 10.18632/oncotarget.6891.

2.

Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.

Browne A, Sriraksa R, Guney T, Rama N, Van Noorden S, Curry E, Gabra H, Stronach E, El-Bahrawy M.

Cytokine. 2013 Oct;64(1):413-21. doi: 10.1016/j.cyto.2013.05.006. Epub 2013 May 30.

PMID:
23727325
3.

MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, Fanayan S, Emmanuel C, Hacker NF, Sutherland RL, Defazio A, O'Brien PM.

BMC Cancer. 2010 Sep 17;10:497. doi: 10.1186/1471-2407-10-497.

4.

The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.

Vitiazeva V, Kattla JJ, Flowers SA, Lindén SK, Premaratne P, Weijdegård B, Sundfeldt K, Karlsson NG.

PLoS One. 2015 Jun 15;10(6):e0130197. doi: 10.1371/journal.pone.0130197. eCollection 2015.

5.

Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels.

Devan SM, Pailoor J, Sthaneshwar P, Narayanan V.

Asian Pac J Cancer Prev. 2013;14(8):4545-8.

6.

MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.

Abdelaal SE, Habib FM, El Din AA, Gabal SM, Hassan NS, Ibrahim NA.

Asian Pac J Cancer Prev. 2016;17(7):3295-300.

7.

High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid.

Boss EA, Moolenaar SH, Massuger LF, Boonstra H, Engelke UF, de Jong JG, Wevers RA.

NMR Biomed. 2000 Aug;13(5):297-305.

PMID:
10960920
8.

Gene expression profiling of human ovarian tumours.

Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage EH, O'Dwyer PJ, Livolsi VA, Johnson SW.

Br J Cancer. 2006 Oct 23;95(8):1092-100. Epub 2006 Sep 12.

9.

Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.

Okła K, Surówka J, Frąszczak K, Czerwonka A, Kaławaj K, Wawruszak A, Kotarski J, Wertel I.

Tumour Biol. 2018 Oct;40(10):1010428318804937. doi: 10.1177/1010428318804937.

PMID:
30319054
10.

The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.

Saied EM, El-Etreby NM.

Ann Diagn Pathol. 2017 Apr;27:62-68. doi: 10.1016/j.anndiagpath.2017.01.006. Epub 2017 Jan 22.

PMID:
28325363
11.

Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary.

Chudecka-Głaz A, Rzepka-Górska I, Kosmowska B.

Arch Gynecol Obstet. 2004 Nov;270(3):151-6. Epub 2003 Jul 23.

PMID:
12883823
12.

Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.

Hasby EA.

Pathol Oncol Res. 2012 Apr;18(2):509-18. doi: 10.1007/s12253-011-9474-8. Epub 2011 Dec 8.

PMID:
22161157
13.

Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.

Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M.

Int J Oncol. 2002 Aug;21(2):315-20.

PMID:
12118327
14.

Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma.

Innamaa A, Jackson L, Asher V, Van Shalkwyk G, Warren A, Hay D, Bali A, Sowter H, Khan R.

Anticancer Res. 2013 Apr;33(4):1401-8.

PMID:
23564779
15.

Ex vivo 1H and 31P magnetic resonance spectroscopy as a means for tumor characterization in ovarian cancer patients.

Abramov Y, Carmi S, Anteby SO, Ringel I.

Oncol Rep. 2013 Jan;29(1):321-8. doi: 10.3892/or.2012.2071. Epub 2012 Oct 5.

PMID:
23042519
16.

Vascular endothelial growth factor in adnexal masses.

Demirkiran F, Kumbak B, Bese T, Arvas M, Benian A, Aydin S, Uzun H, Sanioglu C, Aydinli K, Kösebay D.

Int J Gynaecol Obstet. 2003 Oct;83(1):53-8.

PMID:
14511872
17.

Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.

Yoshida H, Sumi T, Zhi X, Yasui T, Honda K, Ishiko O.

Anticancer Res. 2011 Apr;31(4):1271-7.

PMID:
21508375
18.

Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

McCluggage WG.

Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Review.

PMID:
21716157
19.

Survivin in ovary tumors.

Plewka D, Jakubiec-Bartnik B, Morek M, Bogunia E, Bienioszek M, Wolski H, Kotrych D, Dziekan K, Seremak-Mrozikiewicz A, Plewka A.

Ginekol Pol. 2015 Jul;86(7):525-30.

PMID:
26376531
20.

Vascular endothelial growth factor in ovarian cyst fluid.

Boss EA, Massuger LF, Thomas CM, Geurts-Moespot A, Boonstra H, Sweep CG.

Cancer. 2001 Jan 15;91(2):371-7.

PMID:
11180084

Supplemental Content

Support Center